title: Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias.
abstract: In this study we investigated the pattern of T lymphocyte changes in 16 adult patients with acute myeloid leukaemia (8), non-Hodgkin's lymphoma (4) and Hodgkin's disease (4) treated with continuous infusion of recombinant interleukin-2 (rIL-2). Effects indicative of lymphocyte activation occurred even prior to any rIL-2 therapy in these patients, being most prominent in patients with active diseases. Following each course of cytokine therapy, there were further changes in these parameters. Significant rebound lymphocytoses occurred with a concomitant increase in the cytotoxic functions and induction of the cytotoxicity-linked cytoplasmic serine esterase. Hence, both the natural killer and lectin-dependent cellular cytotoxicity activities were up-regulated. There were also increases in the serum sIL-2 receptor, sCD4 and sCD8 levels. More CD3+ lymphocytes, especially cells bearing CD4, were also recruited to the pool of potential effector cells, as demonstrated by the greater proportion of cells expressing the cytoplasmic serine esterase.
authors.affiliation: Department of Haematology, University College Hospital, London, UK.
authors.forename: S H
authors.initials: SH
authors.lastname: Lim
authors.forename: C
authors.initials: C
authors.lastname: Worman
authors.forename: A
authors.initials: A
authors.lastname: Jewell
authors.forename: C
authors.initials: C
authors.lastname: Tsakona
authors.forename: F J
authors.initials: FJ
authors.lastname: Giles
authors.forename: A
authors.initials: A
authors.lastname: Goldstone
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D003602:Cytotoxicity, Immunologic; D004790:Enzyme Induction; D004950:Esterases / Q000096:biosynthesis*; D006689:Hodgkin Disease / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000628:therapy; D008213:Lymphocyte Activation; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology* / Q000628:therapy; D015375:Receptors, Interleukin-2 / Q000032:analysis; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D015703:Antigens, CD; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D004950:Esterases; C022635:serine esterase